Recent Updates
Recently added Catalysts
RMD Positive Sentiment

Resmed Acquires VirtuOx

Key Takeaway: Resmed has acquired VirtuOx, an independent diagnostic testing facility, to enhance its home healthcare offerings. This acquisition aims to improve care delivery by making it more accessible and coordinated, particularly for patients with sleep-related issues. VirtuOx's virtual testing platform is expected to help streamline the diagnostic process and reduce barriers to treatment. Following the acquisition, VirtuOx will operate as a subsidiary of Resmed, maintaining its brand while continuing to innovate in the healthcare space.
Price reaction · baseline $236.59 (2025-04-30 close) · hit after-hours · 1 other RMD headline(s) in the window, move may be shared
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Resmed strengthens its position in home healthcare with the acquisition.
  • VirtuOx's virtual testing platform enhances accessibility for patients.
  • The acquisition is aimed at reducing barriers to diagnosis for sleep-related conditions.
  • Both companies share a commitment to simplifying healthcare and improving patient outcomes.

Full Press Release Details

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions.
The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx’s at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected way.
VirtuOx’s virtual testing platform helps reduce barriers to diagnosis, offering fast, flexible, and affordable options for patients—particularly those with sleep-disordered breathing or other conditions that are often underdiagnosed. For people suspected of having obstructive sleep apnea (OSA), a more streamlined, digital-first experience can make the difference between following through on testing and treatment—or falling out of the care pathway entirely.
“This is about creating a simpler, more connected pathway to care,” said Justin Leong, Chief Product Officer at Resmed. “By integrating VirtuOx’s diagnostic capabilities into our ecosystem, we can help accelerate the time between evaluation and treatment, reduce drop-off, and help more people access the life-changing benefits of therapy for sleep apnea and related conditions.”
This acquisition strengthens Resmed’s ability to partner with healthcare providers to help streamline the diagnostic process and alleviate current bottlenecks, while expanding collaboration with home medical equipment providers to efficiently and expeditiously support patients to start treatment. It further enhances the company’s ability to serve healthcare providers with integrated tools that improve care coordination, patient engagement, and outcomes.
“VirtuOx and Resmed are aligned in our focus to simplify healthcare and expand access,” said Steve Lica, CEO of VirtuOx. “Joining Resmed gives us the opportunity to scale our impact, reach and help more patients, and keep innovating on behalf of the providers and health systems we serve.”
The acquisition supports a growing demand for home-based care—driven by increased awareness, convenience, and digital innovation. It also creates opportunities to expand into adjacent areas such as insomnia, while deepening Resmed’s relationships with physicians, sleep labs, and home medical equipment providers.
VirtuOx will operate as a fully owned subsidiary of Resmed following the transaction, continuing to serve partners and patients under its existing brand in the near term. The VirtuOx leadership team will remain in place and continue to drive the company’s growth and innovation strategy.
Financial terms are not being disclosed, as the acquisition is not material to Resmed’s financial results.
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
VirtuOx is a software-enabled independent diagnostic testing facility and provider of technology solutions to facilitate in-home and remote testing services for sleep, respiratory, cardiac, and other health conditions across the United States.
Kristen Handley Slater, Resmed
Mike Ott or Wendy Wilson, Resmed

Frequently Asked Questions

What is the recent acquisition announced by Resmed?

Resmed has acquired VirtuOx, an independent diagnostic testing facility for sleep and respiratory conditions.

How will VirtuOx benefit Resmed's patients?

VirtuOx will enhance at-home diagnostic services, helping patients get diagnosed and treated more efficiently.

What does VirtuOx's platform aim to improve?

The platform aims to reduce barriers to diagnosis, making testing faster, flexible, and affordable for patients.

How will the acquisition impact healthcare providers?

It will streamline the diagnostic process and improve care coordination and patient engagement.

Will VirtuOx continue to operate independently?

Yes, VirtuOx will remain a fully owned subsidiary of Resmed and maintain its brand temporarily.

Last updated: May 1, 2025